Chart of the Day: OZEM ETF hoping there is still fuel in the megatrend second only to AI
The OZEM ETF hopes to bank on the mega success of the miraculous weight loss drug, and the list of holdings should be fertile ground for stock pickers looking for a more direct ride on the wave.
Roundhill Investments' GLP-1 & Weight Loss ETF (OZEM), which launched last week, features industry leaders Eli Lilly and Novo Nordisk alongside emerging players in weight loss and diabetes treatment development. CEO Dave Mazza said to CNBC the ETF is tapping into the sector's explosive growth potential. Eli Lilly and Novo Nordisk each make up about 21% of the ETF, while the next three largest holdings—Zealand Pharma, Amgen, and Chugai Pharmaceutical—each have a weighting of less than 5%.
Although it has only been a few days of trading, it's no immediate success so far.
However, if the success of Ozempic continues, the companies further down the list of the ETF's 30 holdings should be a good place to start looking for second and third-order beneficiaries.
